Skip to content

Author

Tianbao Xu

We have 1 of 3 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Aug 2026

NRF2-mediated ferroptosis suppression defines a cancer-specific vulnerability in tumors

This discovery fundamentally redefines the pathological role of NRF2 and positions NRF2 inhibition as a standalone, tumor-selective therapeutic strategy to eliminate Kras-driven malignancies by unleashing ferroptosis.

Dichun Huang, Mae Zhang, Ben N Stansfield et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.